Craft

Ipsen

Stock Price

€113.2

2024-10-29

Market Capitalization

€9.4 B

2024-10-29

Revenue

€3.4 B

FY, 2024

Ipsen Summary

Company Summary

Overview
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014 in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. The Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative technological platforms, peptides and toxins, located in the heart of the leading biotechnological hubs (Les Ulis, Fr ; Slough/Oxford, UK ; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million (about 15% of Group sales). The Group has more than 4,500 employees.
Type
Public
Status
Active
Founded
1929
HQ
Boulogne-Billancourt, FR | view all locations
Website
https://www.ipsen.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Marc de Garidel
  • Shahrzad Amirani

    Shahrzad Amirani, Vice President, Head of New Products and Innovation

  • Brad Carter

    Brad Carter, Senior Director, Finance and Supply Chain

  • Dominique Bery

    Dominique Bery, Executive Vice President, Strategy and Transformation

LocationsView all

49 locations detected

  • Boulogne-Billancourt, IDF HQ

    France

    65 Quai Georges Gorse

  • Berkeley Heights, NJ

    United States

    200 Connell Drive Suite

  • Cambridge, MA

    United States

    One Kendall Square

  • Cambridge, MA

    United States

    One Main Street

  • Algiers, Wilaya d'Alger

    Algeria

    9 Chem. de Val d'Hydra

  • South Yarra, VIC

    Australia

    627 Chapel St

and 43 others

Ipsen Financials

Summary Financials

Revenue (FY, 2024)
€3.4B
Gross profit (FY, 2024)
€3.3B
Net income (FY, 2024)
€356.8M
Cash (FY, 2024)
€678.1M
EBIT (FY, 2024)
€401.1M
Enterprise value
$9.2B

Footer menu